DE69802918D1 - Vwf propeptide enthaltendes pharmazeutisches präparat - Google Patents

Vwf propeptide enthaltendes pharmazeutisches präparat

Info

Publication number
DE69802918D1
DE69802918D1 DE69802918T DE69802918T DE69802918D1 DE 69802918 D1 DE69802918 D1 DE 69802918D1 DE 69802918 T DE69802918 T DE 69802918T DE 69802918 T DE69802918 T DE 69802918T DE 69802918 D1 DE69802918 D1 DE 69802918D1
Authority
DE
Germany
Prior art keywords
pharmaceutical preparation
containing pharmaceutical
vwf propeptide
propeptide containing
vwf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69802918T
Other languages
English (en)
Other versions
DE69802918T2 (de
Inventor
Hans-Peter Schwarz
Katalin Varadi
Peter Turecek
Coenraad Hemker
Lucette Beguin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxalta Innovations GmbH
Original Assignee
Baxter AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter AG filed Critical Baxter AG
Publication of DE69802918D1 publication Critical patent/DE69802918D1/de
Application granted granted Critical
Publication of DE69802918T2 publication Critical patent/DE69802918T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69802918T 1997-05-28 1998-05-26 Vwf propeptide enthaltendes pharmazeutisches präparat Expired - Lifetime DE69802918T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0091797A AT405485B (de) 1997-05-28 1997-05-28 Eine das vwf-propeptid enthaltende pharmazeutische präparation
PCT/EP1998/003090 WO1998053848A1 (en) 1997-05-28 1998-05-26 PHARMACEUTICAL PREPARATION COMPRISING vWF PROPEPTIDE

Publications (2)

Publication Number Publication Date
DE69802918D1 true DE69802918D1 (de) 2002-01-24
DE69802918T2 DE69802918T2 (de) 2003-04-10

Family

ID=3502803

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69802918T Expired - Lifetime DE69802918T2 (de) 1997-05-28 1998-05-26 Vwf propeptide enthaltendes pharmazeutisches präparat

Country Status (10)

Country Link
US (2) US7005502B1 (de)
EP (1) EP0977584B1 (de)
JP (1) JP4335978B2 (de)
AT (2) AT405485B (de)
AU (1) AU744643B2 (de)
CA (1) CA2288737A1 (de)
DE (1) DE69802918T2 (de)
ES (1) ES2168766T3 (de)
NO (1) NO324064B1 (de)
WO (1) WO1998053848A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4663837B2 (ja) * 1999-12-24 2011-04-06 一般財団法人化学及血清療法研究所 第▲ｖｉｉｉ▼因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物
CN1208088C (zh) 1999-12-24 2005-06-29 财团法人化学及血清疗法研究所 预防和治疗与血小板紊乱有关的出血性疾病的药用组合物
ES2434035T3 (es) 2004-12-27 2013-12-13 Baxter International Inc. Conjugados de polímero-factor von Willebrand
BRPI0708832A2 (pt) 2006-03-31 2011-06-14 Baxter Int construÇço proteinÁcea
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
TWI600437B (zh) 2007-12-28 2017-10-01 巴克斯歐塔公司 重組ｖｗｆ調配物
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
ES2298096B1 (es) * 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
JP5781931B2 (ja) 2008-10-21 2015-09-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 凍結乾燥した組換え型ｖｗｆ製剤
JP5749649B2 (ja) * 2008-10-27 2015-07-15 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 血栓性血小板減少性紫斑病のモデルおよびその使用方法
CA2771232A1 (en) 2009-08-20 2011-02-24 Baxter International Inc. Purification of vwf for increased removal of non-lipid enveloped viruses
US20110150843A1 (en) * 2009-10-30 2011-06-23 National Institute Of Immunology Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
WO2017055072A1 (en) 2015-10-02 2017-04-06 Asml Netherlands B.V. Metrology method and apparatus, computer program and lithographic system
EP3648788B1 (de) 2017-07-07 2024-05-22 Takeda Pharmaceutical Company Limited Behandlung von magen-darm-blutung bei patienten mit schwerer von-willebrand-krankheit durch verabreichung von rekombinantem vwf
CN111565741A (zh) 2017-07-07 2020-08-21 百深公司 通过施用重组vwf来治疗经历择期手术的患有严重冯维勒布兰德病的患者
SG11202009213TA (en) 2018-03-21 2020-10-29 Baxalta Inc Separation of vwf and vwf propeptide by chromatographic methods
EP3917557A1 (de) 2019-02-01 2021-12-08 Takeda Pharmaceutical Company Limited Verfahren zur prophylaktischen behandlung mittels rekombinanter vwf (rvwf)
EP4028046B1 (de) 2019-09-11 2024-02-14 Takeda Pharmaceutical Company Limited Verfahren zur behandlung im zusammenhang mit komplexen des von-willebrand-faktors und komplement c1q
MX2022009492A (es) 2020-02-04 2022-11-09 Takeda Pharmaceuticals Co Tratamiento de la menorragia en pacientes con enfermedad de von willebrand grave mediante la administración de factor de von willebrand (fvw) recombinante.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT350726B (de) 1976-08-30 1979-06-11 Immuno Ag Verfahren zur herstellung einer blut- gerinnungsfoerdernden praeperation aus menschlichem blutplasma
AT368883B (de) 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
AT378005B (de) 1983-08-20 1985-06-10 Linde Ag Verfahren zum desoxidieren von metallschmelzen
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
AT390560B (de) 1986-05-30 1990-05-25 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
US5849536A (en) * 1990-03-02 1998-12-15 Bio-Technology General Corp. Cloning and production of human von willebrand factor GPIb binding domain polypeptides and methods of using same
FR2673632A1 (fr) * 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
AT398079B (de) 1991-11-04 1994-09-26 Immuno Ag Präparation mit thrombinaktivität sowie verfahren zu ihrer herstellung
WO1994013329A1 (de) 1992-12-16 1994-06-23 Immuno Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
AT402788B (de) 1993-08-03 1997-08-25 Immuno Ag Virussichere blutgerinnungsfaktor xiii-präparation
JPH07330797A (ja) 1994-05-31 1995-12-19 Sumitomo Metal Ind Ltd 新規細胞接着活性ペプチド
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
AT404554B (de) 1996-04-29 1998-12-28 Immuno Ag Pharmazeutische präparation
US6068838A (en) 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
AT404359B (de) 1996-04-29 1998-11-25 Immuno Ag Gereinigte multimerase

Also Published As

Publication number Publication date
AU744643B2 (en) 2002-02-28
JP4335978B2 (ja) 2009-09-30
US7005502B1 (en) 2006-02-28
ATA91797A (de) 1999-01-15
US7557188B2 (en) 2009-07-07
AT405485B (de) 1999-08-25
WO1998053848A1 (en) 1998-12-03
NO324064B1 (no) 2007-08-06
NO995843L (no) 2000-01-27
DE69802918T2 (de) 2003-04-10
JP2001527579A (ja) 2001-12-25
NO995843D0 (no) 1999-11-29
AU7915698A (en) 1998-12-30
ES2168766T3 (es) 2002-06-16
EP0977584A1 (de) 2000-02-09
ATE210455T1 (de) 2001-12-15
CA2288737A1 (en) 1998-12-03
US20060003921A1 (en) 2006-01-05
EP0977584B1 (de) 2001-12-12

Similar Documents

Publication Publication Date Title
DE69802918D1 (de) Vwf propeptide enthaltendes pharmazeutisches präparat
ATE262336T1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
NO179531C (no) Fremgangsmåte for brönnbehandling
DE69616333T2 (de) Thip zur behandlung von schlafstörungen
PT841928E (pt) Formulacao de libertacao prolongada de d-trep-metilfenidato
PT83872B (pt) Processo de preparacao de compostos de fosforo e de medicamentos contendo-os
DE3772429D1 (de) Pharmazeutisches praeparat zur behandlung von peridontalkrankheiten.
EA199700170A1 (ru) Способ получения некоторых азациклогексапетидов
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
PT93959A (pt) Processo para a preparacao de derivados de sacarina uteis como inibidores proteoliticos de enzima
ATE202483T1 (de) Immuntolerante prothrombinkomplex-präparation
ATE239474T1 (de) Verwendung von levobupivacain
DE3681642D1 (de) Benzopyran-verbindungen zur behandlung von inkontinenz.
EA199800866A1 (ru) Способ снятия боли
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE223721T1 (de) Edelfosin zur behandlung von hirntumoren
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
DE69736180D1 (de) Behandlung von manischen erkrankungen
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
NO995132L (no) Fremgangsmåte for reduksjon av fibrinogen
DK0795008T3 (da) Humane hypertrofe chondrocyt-cellelinjer
DE68926222D1 (de) Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen
NO984198L (no) FremgangsmÕte for behandling av aggresjon
DE68905479D1 (de) Transdermate magensafthemmende wirkstoffe zur behandlung von magen-darm-erkrankungen.
ATE62120T1 (de) Laser zur medizinischen behandlung kranker bereiche organischen gewebes.

Legal Events

Date Code Title Description
8332 No legal effect for de
8328 Change in the person/name/address of the agent

Free format text: HOFFMANN * EITLE, 81925 MUENCHEN

8370 Indication related to discontinuation of the patent is to be deleted
8327 Change in the person/name/address of the patent owner

Owner name: BAXTER INNOVATIONS GMBH, WIEN, AT